FDCA Carried Out “Absolutely Perfunctory, Premeditated And Peripheral Inquiry”: Dhanani To HC

Ahmedabad : Leader of Opposition in Gujarat Assembly, Paresh Dhanani, has termed the preliminary inquiry by the Food and Drug Control Administration (FDCA) that gave a clean chit to BJP state chief CR Paatil who distributed Covid drug from BJP office in Surat as “politically motivated and completely biased”.

In a rejoinder affidavit filed before the Gujarat High Court in connection with his petition on the “illegal distribution” of Remdesivir, Dhanani has relied on the Delhi High Court order that expressed dissatisfaction with the Drug Controller’s investigation and clean chit to BJP MP Gautam Gambhir and AAP MLAs of Delhi, who had distributed Fabiflu in Delhi during the peak of second wave of the Covid pandemic.

Navsari MP and Gujarat BJP president CR Paatil and MLA Harsh Sanghvi courted controversy in April when amid a dire shortage of the antiviral drug Remdesivir, Paatil had announced that 5,000 vials of the drug would be given free of cost to needy patients from Surat BJP office.

Contesting the clean chit given by Food and Drug Control Administration (FDCA) to Paatil and Sanghavi based on preliminary inquiry, a report of which was filed before the HC, Dhanani submitted that the FDCA has carried out “absolutely perfunctory, premeditated and peripheral inquiry inconsistent with the statutory obligation and devoid of their statutory functions and duties”.

Dhanani highlighted that his PIL raises two fundamental questions — one about two elected representatives belonging to BJP taking lead in purchasing, collecting, hoarding and distributing Remdesivir on charity from the BJP office with a political overtone and the second “abject failure on the part of Respondent 7 (FDCA)” in implementing Central government’s directives and failing to ensure that “no private individuals or association collects Remdesivir injection in large number and distributes the same in private initiative”. The matter has been posted for further hearing for August 4.

  • Related Posts

    India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

    The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

    India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

    Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

    India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

    India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

    India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

    India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

    India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

    Novo Nordisk gears up for December Ozempic launch

    Novo Nordisk gears up for December Ozempic launch

    Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

    Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

    Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

    Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit